Business Description
Haisco Pharmaceutical Group Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100001BC7
Share Class Description:
SZSE:002653: Class ACompare
Compare
Traded in other countries / regions
002653.China IPO Date
2012-01-17Description
Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.74 | |||||
| Equity-to-Asset | 0.63 | |||||
| Debt-to-Equity | 0.47 | |||||
| Debt-to-EBITDA | 4.94 | |||||
| Interest Coverage | 12.98 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 9.26 | |||||
| Beneish M-Score | -2.29 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -0.2 | |||||
| 3-Year EBITDA Growth Rate | -12.1 | |||||
| 3-Year EPS without NRI Growth Rate | 16.3 | |||||
| 3-Year Book Growth Rate | 11.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 87.74 | |||||
| 9-Day RSI | 77.9 | |||||
| 14-Day RSI | 71.95 | |||||
| 6-1 Month Momentum % | 5.56 | |||||
| 12-1 Month Momentum % | 3.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.89 | |||||
| Quick Ratio | 1.7 | |||||
| Cash Ratio | 1.01 | |||||
| Days Inventory | 112.61 | |||||
| Days Sales Outstanding | 76.08 | |||||
| Days Payable | 56.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.2 | |||||
| Shareholder Yield % | 0.53 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 70.21 | |||||
| Operating Margin % | 14.54 | |||||
| Net Margin % | 10.29 | |||||
| FCF Margin % | 1.83 | |||||
| ROE % | 8.76 | |||||
| ROA % | 5.5 | |||||
| ROIC % | 9.53 | |||||
| ROC (Joel Greenblatt) % | 24.69 | |||||
| ROCE % | 8.1 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 94.88 | |||||
| PE Ratio without NRI | 92 | |||||
| Shiller PE Ratio | 78.42 | |||||
| PEG Ratio | 30.67 | |||||
| PS Ratio | 9.83 | |||||
| PB Ratio | 7.87 | |||||
| Price-to-Tangible-Book | 16.24 | |||||
| Price-to-Free-Cash-Flow | 379.5 | |||||
| Price-to-Operating-Cash-Flow | 72.81 | |||||
| EV-to-EBIT | 83.35 | |||||
| EV-to-EBITDA | 83.35 | |||||
| EV-to-Revenue | 9.86 | |||||
| EV-to-FCF | 539.16 | |||||
| Price-to-Projected-FCF | 25.09 | |||||
| Price-to-Median-PS-Value | 1.26 | |||||
| Price-to-Graham-Number | 8.14 | |||||
| Price-to-Net-Current-Asset-Value | 116.77 | |||||
| Earnings Yield (Greenblatt) % | 1.2 | |||||
| FCF Yield % | 0.19 | |||||
| Forward Rate of Return (Yacktman) % | -10.3 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Haisco Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,483.56 | ||
| EPS (TTM) (Â¥) | 0.32 | ||
| Beta | 0.54 | ||
| Volatility % | 30.48 | ||
| 14-Day RSI | 71.95 | ||
| 14-Day ATR (Â¥) | 1.116023 | ||
| 20-Day SMA (Â¥) | 27.087 | ||
| 12-1 Month Momentum % | 3.04 | ||
| 52-Week Range (Â¥) | 18.59 - 30.6 | ||
| Shares Outstanding (Mil) | 1,114.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Haisco Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Haisco Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Haisco Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Haisco Pharmaceutical Group Co Ltd(SZSE:002653)'s stock price today?
The current price of SZSE:002653 is ¥30.36. The 52 week high of SZSE:002653 is ¥30.60 and 52 week low is ¥18.59.
When is next earnings date of Haisco Pharmaceutical Group Co Ltd(SZSE:002653)?
The next earnings date of Haisco Pharmaceutical Group Co Ltd(SZSE:002653) is .
Does Haisco Pharmaceutical Group Co Ltd(SZSE:002653) pay dividends? If so, how much?
Haisco Pharmaceutical Group Co Ltd(SZSE:002653) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers